Cardiac Prosthetic Devices

Global Cardiac Prosthetic Devices Market to Reach US$11.9 Billion by 2030

The global market for Cardiac Prosthetic Devices estimated at US$7.9 Billion in the year 2024, is expected to reach US$11.9 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Implantable Pacemakers, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the External Pacemakers segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 10.8% CAGR

The Cardiac Prosthetic Devices market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Cardiac Prosthetic Devices Market – Key Trends & Drivers Summarized

What Are Cardiac Prosthetic Devices, and Why Are They Crucial for Cardiac Care?

Cardiac prosthetic devices are medical implants used to support or replace damaged or failing components of the heart, offering life-saving solutions for patients with various heart conditions. These devices include heart valves, pacemakers, defibrillators, and ventricular assist devices (VADs), which play a pivotal role in managing structural heart diseases, arrhythmias, and heart failure. With the rising global incidence of cardiovascular diseases (CVDs), especially heart valve disorders and heart failure, cardiac prosthetic devices have become critical in modern cardiology.

Heart valve replacements are among the most commonly used cardiac prosthetic devices. They address issues like valve stenosis or regurgitation by replacing faulty valves with mechanical or biological alternatives. Devices like pacemakers and implantable cardioverter defibrillators (ICDs) help manage abnormal heart rhythms, while VADs are used to support heart function in patients awaiting heart transplants or for those with advanced heart failure. As cardiovascular disease remains the leading cause of death worldwide, cardiac prosthetic devices are essential for improving the quality of life and survival rates of affected patients.

How Are Technological Advancements Shaping the Cardiac Prosthetic Devices Market?

Technological advancements are revolutionizing the cardiac prosthetic devices market by improving device performance, patient outcomes, and procedural success rates. Innovations in materials science have led to the development of more durable and biocompatible heart valves. For instance, newer mechanical valves are designed to last a lifetime, reducing the need for repeat surgeries, while biological valves, often derived from animal tissue, offer a lower risk of clotting without requiring long-term blood thinners. Additionally, transcatheter heart valve replacement technologies, such as transcatheter aortic valve replacement (TAVR), have gained significant traction. TAVR is a minimally invasive procedure that allows valve replacement without the need for open-heart surgery, reducing recovery time and associated risks. Leadless pacemakers, which are smaller and easier to implant, offer less risk of infection and other complications. Similarly, next-generation ICDs come with enhanced programming to better detect and treat life-threatening arrhythmias, improving patient outcomes. Furthermore, advancements in VADs are making these devices more compact, reliable, and easier to manage for patients with advanced heart failure. The integration of digital health technologies, such as remote monitoring and wireless connectivity, is enabling real-time patient monitoring, early detection of device complications, and better post-implant care, further advancing the cardiac prosthetic devices market.

What Patient and Healthcare Trends Are Driving the Demand for Cardiac Prosthetic Devices?

Several healthcare and patient trends are driving the growing demand for cardiac prosthetic devices. The aging global population is one of the primary factors, as older individuals are more susceptible to cardiovascular diseases, particularly valvular heart diseases and heart failure. As life expectancy continues to rise, the need for heart valve replacements, pacemakers, and other cardiac devices is also increasing. Additionally, younger patients diagnosed with congenital heart defects or early-onset cardiovascular conditions are benefiting from advancements in prosthetic devices that offer long-term solutions, making these devices crucial for patients across various age groups.

Another significant trend is the rising preference for minimally invasive procedures. Patients are increasingly seeking treatments that offer quicker recovery times, fewer complications, and shorter hospital stays. Technologies like TAVR, transcatheter mitral valve repair (TMVR), and minimally invasive pacemaker implantation cater to this demand, enabling more patients to undergo life-saving procedures without the risks associated with open-heart surgery. The expanding availability of these procedures in more regions is making cardiac prosthetic devices accessible to a broader population.

Moreover, the growing focus on patient-centric care and the rise of digital health are influencing demand. Patients and healthcare providers now have access to devices that allow for remote monitoring, enabling better post-procedure follow-up and personalized care. These advancements improve the management of chronic conditions, reduce hospital readmissions, and enhance patient satisfaction, further driving demand for cardiac prosthetic devices.

Growth in the Cardiac Prosthetic Devices Market Is Driven by Several Factors

Growth in the cardiac prosthetic devices market is driven by several factors, including the rising prevalence of cardiovascular diseases, the growing aging population, and advancements in medical technologies. One of the key drivers is the increasing incidence of heart valve disorders and arrhythmias, particularly among older adults. As heart valve disease becomes more common with age, the demand for prosthetic heart valves, both mechanical and biological, is rising. Minimally invasive procedures like TAVR are gaining popularity due to their lower risks and faster recovery times, contributing significantly to market expansion.

Technological advancements are another crucial factor driving growth. Innovations such as leadless pacemakers, enhanced ICDs, and compact VADs are improving patient outcomes and expanding the range of patients eligible for treatment. The ability to integrate cardiac prosthetic devices with digital health tools is enabling real-time monitoring and better management of patients with chronic cardiovascular conditions, making these devices more effective and appealing to both patients and healthcare providers.

Additionally, the growing focus on preventive healthcare and early diagnosis is increasing the adoption of cardiac prosthetic devices as part of comprehensive cardiovascular care strategies. The expansion of healthcare infrastructure in developing regions, coupled with increased awareness about heart health, is also creating new opportunities for the market. As healthcare systems worldwide work to address the growing burden of cardiovascular diseases, the demand for advanced, durable, and patient-friendly cardiac prosthetic devices is expected to continue its upward trajectory.

SCOPE OF STUDY:

The report analyzes the Cardiac Prosthetic Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Implantable Pacemakers, External Pacemakers, Transcatheter Heart Valves, Tissue Heart Valves, Mechanical Heart Valves)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Abiomed, Inc.
• AtriCure, Inc.
• Biotronik
• Boston Scientific Corporation
• Braile Biomedica
• CryoLife, Inc.
• Edwards Lifesciences Corporation
• Labcor Laboratrios
• Lepu Medical Technology Co,. Ltd.
• Lifetech Scientific
• LivaNova
• Medtronic plc.
• Meril Life Sciences Pvt. Ltd.
• MicroPort Scientific
• Shree Pacetronix
• Siemens Healthcare GmbH
• Sorin Group
• St. Jude Medical, Inc.
• TTK Healthcare
• Venus Medtech
• Vitatron

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.